Puma Biotechnology, Inc. (PBYI) · Nov 5, 2026 · Earnings
Miss — Revenue $55.1M vs ~$57.5M consensus
Puma Biotechnology’s third-quarter earnings show growing NERLYNX demand, but revenue missed expectations and full-year sales guidance narrowed lower as gross-to-net pressure rose.
Puma is a one-product commercial biotech using NERLYNX cash flow to fund the higher-risk alisertib pipeline in breast cancer and small-cell lung cancer; the prior quarter had already raised full-year revenue and net-income guidance on stronger NERLYNX demand.
The quarter missed on the top line, despite an EPS beat. Total revenue was $55.1 million, below the published consensus of roughly $57.5 million, while diluted GAAP EPS of $0.11 was above the roughly $0.09 expectation. The miss was concentrated in revenue: NERLYNX product revenue rose 4.2% year over year, but royalty revenue fell sharply and the company recorded a $2.1 million royalty reduction tied to generic-market-share data in China.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Product revenue, net (Revenue) | $54.1M (+4.2%) | $51.9M | |
| Royalty revenue (Revenue) | $1.0M (-61.5%) | $2.6M | |
| Total revenue (Revenue) | $55.1M (+1.1%) | $54.5M | ~$57.5M |
| Diluted EPS (Income Statement) | $0.11 (-35.3%) | $0.17 | ~$0.09 |
| R&D expense (Revenue) | $18.3M (+15.1%) | $15.9M |
The core commercial signal is weaker than management’s headline suggests. Management said U.S. NERLYNX demand increased, but higher Medicaid and 340B mix pushed gross-to-net adjustments above expectations, while delayed ex-U.S. partner sales moved from the third quarter into the fourth. That makes the product-growth story real but less profitable and less dependable quarter to quarter.
Puma is spending more to build the alisertib story, but the payoff remains clinical rather than financial. Nine-month R&D expense increased $11.8 million, primarily because clinical-trial costs rose $8.9 million as ALISCA activity expanded. The company initiated ALISCA-Lung2 during the quarter and continues enrollment in its breast and lung studies, which advances the pipeline, but this filing provides no efficacy readout. 〔0〕
The revised outlook is mixed, with the quality of earnings improving more than the business outlook. Full-year total-revenue guidance moved to $224–$227 million from $224–$231 million, while net-income guidance rose to $20–$22 million from $17–$20 million. The higher profit range reflects better financing economics after debt repayment, not a major acceleration in revenue; gross-to-net guidance also increased to 27.5%–28% from 26.5%–27.5%. Cash and marketable securities reached $108.5 million, and nine-month operating cash flow improved to $31.6 million, giving Puma room to keep funding the trials.
Bottom line: This was a mixed quarter that leans negative: NERLYNX demand is growing and the pipeline is advancing, but revenue missed, royalty economics deteriorated, and full-year sales guidance narrowed lower. The next meaningful test is whether alisertib data can eventually justify the increased development spending.
ALISCA-Breast1 data at San Antonio Breast Cancer Symposium, December 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!